Emerald Acquisition Ltd. acquired a new stake in shares of Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) during the second quarter, according to its most recent filing with the SEC. The fund acquired 86,211 shares of the company’s stock, valued at approximately $854,000. Emerald Acquisition Ltd. owned approximately 0.83% of Dipexium Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new position in shares of Dipexium Pharmaceuticals during the first quarter valued at approximately $1,062,000. Falcon Point Capital LLC raised its position in shares of Dipexium Pharmaceuticals by 12.5% in the second quarter. Falcon Point Capital LLC now owns 38,833 shares of the company’s stock valued at $385,000 after buying an additional 4,315 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Dipexium Pharmaceuticals by 9.1% in the first quarter. Geode Capital Management LLC now owns 33,170 shares of the company’s stock valued at $315,000 after buying an additional 2,759 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Dipexium Pharmaceuticals by 51.5% in the first quarter. Renaissance Technologies LLC now owns 25,900 shares of the company’s stock valued at $246,000 after buying an additional 8,800 shares during the last quarter. 24.78% of the stock is owned by hedge funds and other institutional investors.
Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) traded down 0.55% during trading on Wednesday, reaching $14.50. 22,890 shares of the company’s stock were exchanged. Dipexium Pharmaceuticals Inc. has a 52 week low of $6.04 and a 52 week high of $17.75. The stock has a 50-day moving average of $14.00 and a 200-day moving average of $11.58. The stock’s market capitalization is $150.77 million.
Dipexium Pharmaceuticals (NASDAQ:DPRX) last announced its earnings results on Thursday, August 4th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.02. On average, equities research analysts anticipate that Dipexium Pharmaceuticals Inc. will post ($2.10) EPS for the current year.
Separately, Zacks Investment Research lowered shares of Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th.
Dipexium Pharmaceuticals Company Profile
Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).